for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Endo International PLC

ENDP.O

Latest Trade

4.88USD

Change

0.05(+0.93%)

Volume

21,299,690

Today's Range

4.75

 - 

5.18

52 Week Range

1.97

 - 

18.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.83
Open
5.14
Volume
21,299,690
3M AVG Volume
175.03
Today's High
5.18
Today's Low
4.75
52 Week High
18.25
52 Week Low
1.97
Shares Out (MIL)
226.39
Market Cap (MIL)
941.79
Forward P/E
1.92
Dividend (Yield %)
--

Next Event

Q3 2019 Endo International PLC Earnings Call

Latest Developments

More

Endo Announces Successful Culmination Of Litigation Regarding FDA Compounding Policy

Fitch Says U.S. Collateralized Loan Obligations Fairly Insulated From Pharma Sector's Opioid Issue

Endo Announces Submission Of Biologics License Application To FDA For CCH In Patients With Cellulite

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Endo International PLC

Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX. Its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The Company's generics portfolio has a range of dosage forms and delivery systems. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.

Industry

Biotechnology & Drugs

Contact Info

Minerva House, Simmonscourt Road

+353.1.2682000

http://www.endo.com

Executive Leadership

Roger H. Kimmel

Independent Chairman of the Board

Paul V. Campanelli

President, Chief Executive Officer, Director

Blaise Coleman

Chief Financial Officer, Executive Vice President

Terrance John Coughlin

Chief Operating Officer, Executive Vice President

Patrick Barry

Executive Vice President and Chief Commercial Officer

Key Stats

3.07 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

4.0K

2017

3.5K

2018

2.9K

2019(E)

2.9K
EPS (USD)

2016

4.730

2017

3.840

2018

2.890

2019(E)

2.167
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.32
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
6.35
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-6.10
Return on Equity (TTM)
-4.94

Latest News

Latest News

Drugmakers Endo, Allergan agree to $15 million in settlements in major opioid case

Endo International Plc and Allergan Plc have agreed to pay $15 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.

Drugmaker Endo to pay $10 million to settle opioid lawsuit

Endo International Plc on Tuesday said it had agreed to pay $10 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.

IN BRIEF: Endo competitor seeks stay of FDA bulk drug-compounding ruling

Athenex Inc is seeking to put on hold a ruling that upheld a U.S. Food and Drug Administration policy that bars it from making a compounded blood pressure drug that competes with Endo International PLC's Vasostrict while it pursues an appeal.

Endo settles investor case over withdrawn opioid for $82.5 million

Endo International PLC has agreed to pay $82.5 million to resolve a lawsuit accusing the drugmaker of misleading investors by downplaying the risks of Opana ER before pulling the opioid painkiller from the market at the request of U.S. regulators.

Fed Circuit revives Endo patent on opioid Opana ER

Pharmaceutical company Endo International PLC on Thursday won a federal appeals court ruling that strengthens its patent protection on Opana ER, an opioid painkiller it pulled from the U.S. market in 2017.

Endo gains on favorable FDA drug compounding decision

Endo International Plc said on Friday the U.S. health regulator has decided https://bit.ly/2XGrm1k not to include blood pressure treatment vasopressin in its list of drugs that can be used in compounding, in a boost to the drugmaker that makes the only FDA-approved version...

BRIEF-Paulson & Co Ups Share Stake In Discovery, Endo International

* PAULSON & CO INC CUTS SHARE STAKE IN VISTRA ENERGY CORP TO 3.7 MILLION SHARES FROM 10 MILLION SHARES - SEC FILING

BRIEF-Lannett Acquires Portfolio Of Generic Products From Endo International

* LANNETT ACQUIRES PORTFOLIO OF GENERIC PRODUCTS FROM ENDO INTERNATIONAL

Endo unit settles case ahead of first state court testosterone trial

Endo International's Auxilium unit on Tuesday settled a lawsuit over its testosterone replacement drug, just days before the case was set to go to trial in what would have been the first such legal proceeding at the Philadelphia Court of Common Pleas.

Endo unit cleared of liability in first testosterone replacement trial

A federal jury in Chicago said on Thursday that Endo International's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim.

U.S. asks drug maker Endo to withdraw opioid amid abuse crisis

As the United States battles a growing opioid abuse crisis, the Food and Drug Administration on Thursday asked Endo International Plc to withdraw from the market its long-lasting opioid painkiller, Opana ER, sending Endo's shares down more than 12 percent.

FDA asks Endo to withdraw Opana ER opioid, shares fall

The U.S. Food and Drug Administration said on Thursday it has asked Endo International to withdraw from the market its long-lasting opioid painkiller Opana ER, sending the company's shares down as much as 13 percent.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up